Methods and compositions for predicting compliance with an antidepressant treatment regimen

• US 20050165115A1
• Filed: 12/09/2004
• Published: 07/28/2005
• Est. Priority Date: 12/10/2003
• Status: Abandoned Application

• Current Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Original Assignee: Board of Trustees of the Leland Stanford Junior University (Stanford Management Co.)
• Inventors: Schatzberg, Alan F., Murphy, Greer M.
• Application Number:
  US11/010,244
• Publication Number:
  US 20050165115A1
• Time in Patent Office: Days
• US Class Current: 514/649
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

Methods and compositions are provided for predicting whether a subject will comply with an antidepressant treatment regimen. In practicing the subject methods, a subject'"'"'s serotonin transporter gene-linked polymorphic region (5HTTLPR) is genotyped. Based on the identified genotype, a particular antidepressant treatment regimen suitable for the patient is determined. Also provided are kits for practicing the subject methods.

Claims

1. A method of predicting whether a subject will comply with an antidepressant treatment regimen, said method comprising:

determining said subject'"'"'s serotonin transporter gene-linked polymorphic region (5HTTLPR) genotype;

using said determined genotype to predict whether said subject will comply with said antidepressant treatment regimen.

2. The method according to claim 1, wherein said antidepressant treatment regimen comprises administration of an antidepressant agent to said subject.

3. The method according to claim 1, wherein said subject is a human.

4. The method according to claim 3, wherein said human subject possesses major depressive disorder (MDD).

5. The method according to claim 2, wherein said antidepressant agent is a serotonin selective reuptake inhibitor (SSRI) so that said antidepressant treatment regimen is a SSRI treatment regimen.

6. The method according to claim 5, wherein a 5HTTLPR Long/Long (L/L) genotype indicates an increased compliance with a SSRI treatment regimen.

7. The method according to claim 5, wherein said SSRI is paroxetine.

8. The method according to claim 2, where said antidepressant agent is a noradrenergic and specific serotonergic antidepressant so that said antidepressant treatment regimen is a noradrenergic and specific serotonergic antidepressant treatment regimen.

9. The method according to claim 8, wherein a 5HTTLPR Short/Short (S/S) genotype indicates an increased compliance with a noradrenergic and specific serotonergic antidepressant treatment regimen.

10. The method according to claim 8, wherein said noradrenergic and specific serotonergic antidepressant is mirtazapine.

11. The method according to claim 1, further including:

using said prediction to determine an antidepressant treatment regimen for said subject.

12. A method of predicting whether a subject will comply with a serotonin selective reuptake inhibitor (SSRI) treatment regimen, said method comprising:

determining said subject'"'"'s serotonin transporter gene-linked polymnorphic region (5HTTLPR) genotype; and

using said determined genotype to predict whether said subject will comply with said SSRI treatment regimen.

13. The method according to claim 12, wherein one form of said 5HTTLPR genotype indicates a decreased compliance to a SSRI treatment regimen, compared to other forms of said 5HTTLPR genotype.

14. The method according to claim 12, wherein said subject is a human.

15. The method according to claim 14, wherein said human subject possesses major depressive disorder (MDD).

16. The method according to claim 12, wherein a 5HTTLPR Long/Long (L/L) genotype indicates an increased compliance with a SSRI treatment regimen.

17. The method according to claim 16, wherein said SSRI treatment regimen comprises administration of paroxetine to said subject.

18. The method according to claim 12, further including:

using said prediction to determine an antidepressant treatment regimen for said subject.

19. A method of predicting whether a subject will comply with a noradrenergic and specific serotonergic antidepressant treatment regimen, said method comprising:

determining said subject'"'"'s serotonin transporter gene-linked polymnorphic region (5HTTLPR) genotype; and

using said determined genotype to predict whether said subject will comply with said noradrenergic and specific serotonergic antidepressant treatment regimen.

20. The method according to claim 19, wherein one form of said 5HTTLPR genotype indicates a decreased compliance to a noradrenergic and specific serotonergic antidepressant treatment regimen, compared to other forms of said 5HTTLPR genotype.

21. The method according to claim 19, wherein said subject is a human.

22. The method according to claim 21, wherein said human subject possesses major depressive disorder (MDD).

23. The method according to claim 19, wherein a 5HTTLPR Short/Short (S/S) genotype indicates an increased compliance with a noradrenergic and specific serotonergic antidepressant treatment regimen.

24. The method according to claim 23, wherein said noradrenergic and specific serotonergic antidepressant treatment regimen comprises administration of mirtazapine to said subject.

25. The method according to claim 19, further including:

using said prediction to determine a noradrenergic and specific serotonergic antidepressant treatment regimen for said subject.

26. A method of predicting whether a subject will discontinue an antidepressant treatment regimen, said method comprising:

determining said subject'"'"'s serotonin transporter gene-linked polymorphic region (5HTTLPR) genotype;

using said determined genotype to predict whether said subject will discontinue said antidepressant treatment regimen.

27. The method according to claim 26, wherein said antidepressant treatment regimen comprises administration of an antidepressant agent to said subject.

28. The method according to claim 26, wherein said subject is a human.

29. The method according to claim 28, wherein said human subject possesses major depressive disorder (MDD).

30. The method according to claim 27, wherein said antidepressant agent is a serotonin selective reuptake inhibitor (SSRI) so that said antidepressant treatment regimen is a SSRI treatment regimen.

31. The method according to claim 30, wherein a 5HTTLPR Long/Long (L/L) genotype indicates an increased compliance with a SSRI treatment regimen.

32. The method according to claim 30, wherein said SSRI is paroxetine.

33. The method according to claim 27, where said antidepressant agent is a noradrenergic and specific serotonergic antidepressant so that said antidepressant treatment regimen is a noradrenergic and specific serotonergic antidepressant treatment regimen.

34. The method according to claim 33, wherein a 5HTTLPR Short/Short (S/S) genotype indicates an increased compliance with a noradrenergic and specific serotonergic antidepressant treatment regimen.

35. The method according to claim 33, wherein said noradrenergic and specific serotonergic antidepressant is mirtazapine.

36. The method according to claim 26, further including:

using said prediction to determine an antidepressant treatment regimen for said subject.

37. A method for treating a subject for a depression state, comprising:

determining whether a subject is suffering from a depression state;

determining said subject'"'"'s serotonin transporter gene-linked polymorphic region (5HTTLPR) genotype;

using said determined genotype to select a treatment regimen said subject will comply with; and

administering to said subject said treatment regimen to treat said depression state.

38. A kit comprising

reagents for determining a subject'"'"'s serotonin transporter gene-linked polymnorphic region (5HTTLPR) genotype;

and

instructions for evaluating whether said subject will comply with a serotonin selective reuptake inhibitor (SSRI) treatment regimen.

39. The kit according to claim 38, wherein said kit further included PCR primers.

40. The kit according to claim 38, wherein said kit further included a DNA array.